Originally Posted by
kiwidollabill
Ok, lets try the discussion.....
There is nothing wrong with their 'product', they've developed some nice qPCR assays looking at specific bladder cancer markers. From a technical perspective they aren't quite there yet, as the preparation steps are rather time consuming and not easily adaptable to high throughput OR compatible to existing hardware found in most hospital labs.
However, their go to market strategy is what I question. The easy/less risky (and more profitable in the short term) would be to license the assay to Roche/Qiagen/Abbott etc (all big players well established in the market). For what ever reason, they have chosen not to do this (or the big guys had no interest in their IP = bad sign) and are essentially selling as a service provider. This approach is much more capital heavy, encompasses higher risk and is not easy to scale well (in terms of profitability and sales velocity). The payoff in the end could indeed be massive, however the road will be difficult and there are better alternatives to commercialize that IP.
Also, they could be wiped out very quickly if Roche/Qiagen/Abbott decide to move into this space.